A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia

• Published in: Blood Vol. 123; no. 9; pp. 1302 - 1308
• Main Authors: Byrd, John C., Pagel, John M., Awan, Farrukh T., Forero, Andres, Flinn, Ian W., Deauna-Limayo, Delva P., Spurgeon, Stephen E., Andritsos, Leslie A., Gopal, Ajay K., Leonard, John P., Eisenfeld, Amy J., Bannink, Jeannette E., Stromatt, Scott C., Furman, Richard R.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 27.02.2014; American Society of Hematology
• Subjects: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Antigens, Neoplasm - immunology; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Clinical Trials and Observations; Female; Humans; Immunoglobulin G - adverse effects; Immunoglobulin G - therapeutic use; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Male; Maximum Tolerated Dose; Middle Aged; Protein Engineering; Recombinant Fusion Proteins - adverse effects; Recombinant Fusion Proteins - therapeutic use; Tetraspanins - immunology; Treatment Outcome

Otlertuzumab is a novel humanized anti-CD37 protein therapeutic. This study evaluated the safety of otlertuzumab administered intravenously to patients with chronic lymphocytic leukemia (CLL). Otlertuzumab was administered weekly for up to 8 weeks followed by 1 dose per month for 4 months ranging fr...